mitoxantrone has been researched along with Liver Dysfunction in 6 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the safety and efficacy of mitoxantrone use in hyperbilirubinemic breast cancer patients, a prospectively determined dosage schedule was evaluated in a multi-center trial." | 9.06 | Mitoxantrone use in breast cancer patients with elevated bilirubin. ( Bulcavage, L; Chlebowski, RT; Elashoff, R; Henderson, IC; Rivest, R; Woodcock, T, 1989) |
| "If tamoxifen was given together with adjuvant chemotherapy, no changes in liver function tests were detected." | 6.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| "To determine the safety and efficacy of mitoxantrone use in hyperbilirubinemic breast cancer patients, a prospectively determined dosage schedule was evaluated in a multi-center trial." | 5.06 | Mitoxantrone use in breast cancer patients with elevated bilirubin. ( Bulcavage, L; Chlebowski, RT; Elashoff, R; Henderson, IC; Rivest, R; Woodcock, T, 1989) |
| "Mitoxantrone, a cytotoxic anthracenedione derivative, has given clinical evidence of beneficial activity in breast cancer, lymphoma and leukaemia." | 4.78 | Pharmacokinetics and metabolism of mitoxantrone. A review. ( Blanz, J; Ehninger, G; Proksch, B; Schuler, U; Zeller, KP, 1990) |
| "Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail." | 3.76 | Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. ( Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010) |
| "If tamoxifen was given together with adjuvant chemotherapy, no changes in liver function tests were detected." | 2.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| " Pharmacokinetic and metabolic research is essential to a better understanding of the pharmacological and toxicological activities of drugs and their metabolites." | 1.27 | Extrapolation of preclinical pharmacokinetic data to therapeutic drug use. ( Cano, JP; Fabre, G; Rahmani, R; Richard, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kingwell, E | 1 |
| Koch, M | 1 |
| Leung, B | 1 |
| Isserow, S | 1 |
| Geddes, J | 1 |
| Rieckmann, P | 1 |
| Tremlett, H | 1 |
| Savaraj, N | 1 |
| Lu, K | 1 |
| Manuel, V | 1 |
| Loo, TL | 1 |
| Hirvikoski, PP | 1 |
| Kumpulainen, EJ | 1 |
| Johansson, RT | 1 |
| Ehninger, G | 1 |
| Schuler, U | 1 |
| Proksch, B | 1 |
| Zeller, KP | 1 |
| Blanz, J | 1 |
| Chlebowski, RT | 1 |
| Bulcavage, L | 1 |
| Henderson, IC | 1 |
| Woodcock, T | 1 |
| Rivest, R | 1 |
| Elashoff, R | 1 |
| Rahmani, R | 1 |
| Richard, B | 1 |
| Fabre, G | 1 |
| Cano, JP | 1 |
1 review available for mitoxantrone and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics and metabolism of mitoxantrone. A review.
Topics: Animals; Breast Neoplasms; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Leu | 1990 |
2 trials available for mitoxantrone and Liver Dysfunction
| Article | Year |
|---|---|
Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Topics: Acetyltransferases; Adult; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Com | 1997 |
Mitoxantrone use in breast cancer patients with elevated bilirubin.
Topics: Adenocarcinoma; Breast Neoplasms; Female; Humans; Hyperbilirubinemia; Liver Diseases; Middle Aged; M | 1989 |
3 other studies available for mitoxantrone and Liver Dysfunction
| Article | Year |
|---|---|
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
Topics: Adult; Age Factors; Analgesics; Anemia; Female; Follow-Up Studies; Humans; Liver Diseases; Male; Mid | 2010 |
Pharmacology of mitoxantrone in cancer patients.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Bile; Female; Humans; Kidney; Kinetics; Liver; Liver Di | 1982 |
Extrapolation of preclinical pharmacokinetic data to therapeutic drug use.
Topics: Animals; Benzodiazepines; Biotransformation; Drug Evaluation; Drug Evaluation, Preclinical; Drug Int | 1988 |